CoChat

Glyburide Versus Metformin and Their Combination for the Treatment of Gestational Diabetes Mellitus: A Randomized Controlled Study

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

OBJECTIVE To compare the efficacy and safety of glyburide versus metformin and their combination for the treatment of gestational diabetes mellitus (GDM). RESEARCH DESIGN AND METHODS In this prospective randomized controlled study, we randomly assigned patients with GDM at 13–33 weeks gestation and whose blood glucose was poorly controlled by diet to receive either glyburide or metformin. If optimal glycemic control was not achieved, the other drug was added. If adverse effects occurred, the drug was replaced. If both failed, insulin was given. The primary outcomes were the rate of treatment failure and glycemic control after the first-line medication according to mean daily glucose charts. RESULTS Glyburide was started in 53 patients and metformin in 51. In the glyburide group, the drug failed in 18 (34%) patients due to adverse effects (hypoglycemia) in 6 (11%) and lack of glycemic control in 12 (23%). In the metformin group, the drug failed in 15 (29%) patients, due to adverse effects (gastrointestinal) in 1 (2%) and lack of glycemic control in 14 (28%). Treatment success after second-line therapy was higher in the metformin group than in the glyburide group (13 of 15 [87%] vs. 9 of 18 [50%], respectively; P = 0.03). In the glyburide group, nine (17%) patients were eventually treated with insulin compared with two (4%) in the metformin group (P = 0.03). The combination of the drugs reduced the need for insulin from 33 (32%) to 11 (11%) patients (P = 0.0002). Mean daily blood glucose and other obstetrical and neonatal outcomes were comparable between groups, including macrosomia, neonatal hypoglycemia, and electrolyte imbalance. CONCLUSIONS Glyburide and metformin are comparable oral treatments for GDM regarding glucose control and adverse effects. Their combination demonstrates a high efficacy rate with a significantly reduced need for insulin, with a possible advantage for metformin over glyburide as first-line therapy.

Overview

Integrity signals

Registry

Crossref · 10.2337/dc16-2307

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 21 references

Cited by

See all 118

Metadata

Authors
Nachum, Z., Zafran, N., Salim, R., Hissin, N., Hasanein, J., Gam Ze Letova, Y., Suleiman, A., & Yefet, E.
Affiliations
  • Technion – Israel Institute of Technology (IL)
  • Emek Medical Center (IL)
  • Department of Obstetrics and Gynecology, Emek Medical Center, Afula, Israel
Corresponding author
Yefet, Enav
Venue
Diabetes Care
Published
2017-01-11
Volume
40
Issue
3
Pages
332-337
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2575922435
Cited by
118
References
21
Citations by year
2026: 5 · 2025: 6 · 2024: 4 · 2023: 10 · 2022: 10 · 2021: 37 · 2020: 12 · 2019: 11 · 2018: 16 · 2017: 7
FWCI
14.86
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
gestational diabetes mellitus, glibenclamide, metformin, combination therapy, glycemic control, hypoglycemia, gastrointestinal adverse effects, insulin requirement, first-line therapy, macrosomia, neonatal hypoglycemia, electrolyte imbalance
MeSH terms
Administration, Oral, Adolescent, Adult, Blood Glucose, Drug Therapy, Combination, Female, Glyburide, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Israel, Metformin, Middle Aged, Pregnancy, Prospective Studies, Diabetes, Gestational, Treatment Outcome, Treatment Failure, Sample Size, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glyburide Versus Metformin and Their Combination for the Treatment of Gestational Diabetes Mellitus: A Randomized Controlled Study. https://app.cochat.ai/papers/10.2337/dc16-2307
The paper
Nachum, Z., Zafran, N., Salim, R., Hissin, N., Hasanein, J., Gam Ze Letova, Y., Suleiman, A., & Yefet, E. (2017). Glyburide Versus Metformin and Their Combination for the Treatment of Gestational Diabetes Mellitus: A Randomized Controlled Study. Diabetes Care. https://doi.org/10.2337/dc16-2307

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.